Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

BMB. 2021; 6(0): 190-197


Erythrocyte Sedimentation Rate May Predict Diagnosis Of Lymphoma Without Fine-Needle Aspiration Biopsy: A Retrospective Study

Esra Turan Erkek, Oguz Firat Bozkurt, Melis Demirag Evman.




Abstract

Objective: to assess the relationship between routine blood values recorded before fine-needle aspiration biopsy (FNAB) and final diagnosis in patients whose diagnoses could not be confirmed with FNAB, necessitating surgical excisional biopsy (SEB) as a second invasive procedure.
Method: The data of patients who could not be diagnosed via FNAB and underwent SEB of the cervical lymph node between March 2014 and March 2019 in the Otolaryngology Department of a research hospital were evaluated retrospectively. According to the definitive diagnosis determined by SEB, the cases were divided into 3 groups as follows: (1) benign, (2) other malignancies, (3) lymphoma
Results: The frequency of males in the other malignancies group was significantly higher compared to the other two groups (p = 0.007). Compared to the other two groups, C-reactive protein levels were statistically significantly lower in the benign group (p = 0.001). Erythrocyte sedimentation rate (ESR) in the lymphoma group was significantly higher than the other groups (p 35.5 (AUC = 0.784, 95%CI: 0.708–0.861, p

Key words: Lymphoma; erythrocyte sedimentation rate; c-reactive protein; fine-needle aspiration biopsy






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.